The use of recombinant factor VIIa in a Jehovah’s Witness with auto-immune thrombocytopenia and post-splenectomy haemorrhage.
Management of bleeding in patients who refuse blood transfusion may prove to be a therapeutic challenge, and therefore blood sparing modes of therapy need to be considered. In severe surgical or traumatic bleeding, administration of rFVIIa may result in an effective response and should be considered early in the course of management. – M. Aldouri
Successful use of recombinant factor VIIa in a patient with inhibitor secondary to severe factor XI deficiency.
After using rFVIIa effectively in the treatment of hemophilia patients with inhibitors against factors VIII and IX, this case report illustrates its efficacy in treating a 62-year-old woman with high titer inhibitor against factor XI. The patient received FXI:C to successfully cover several previous surgical procedures, however on this occasion the level of FXI inhibitor […]
